• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review
J Gynecol Oncol. 2023 Mar 6. doi: 10.3802/jgo.2023.34.e49. Online ahead of print.ABSTRACTTo examine the effectiveness of progestin re-treatment for recurrent endometrial intraepithelial neoplasia (EIN), atypical endometrial hyperplasia (AH) and endometrial cancer (EC) following initial fertility-sparing treatment. A comprehensive systematic review and meta-analysis were conducted by an Expert Panel of the Japan Society of Gynecologic Oncology Endometrial Cancer Committee. Multiple search engines, including PubMed/MEDLINE and the Cochrane Database, were searched in December 2021 using the keywords "Endometrial neoplasms," "...
Source: Journal of Gynecologic Oncology - March 17, 2023 Category: OBGYN Authors: Isao Murakami Hiroko Machida Tohru Morisada Yasuhisa Terao Tsutomu Tabata Mikio Mikami Yasuyuki Hirashima Yoichi Kobayashi Tsukasa Baba Satoru Nagase Source Type: research

Oncological outcomes in fertility-sparing treatment in stage IA-G2 endometrial cancer
ConclusionsConservative measures must be considered temporary to allow pregnancy and subsequently perform specific counseling to adopt surgery. Fertility-sparing management is not the current standard of care for young women with EC. It can be employed for patients with early-stage diseases motivated to maintain reproductive function. Indeed, the results are encouraging, but the sample size must be increased.
Source: Frontiers in Oncology - September 16, 2022 Category: Cancer & Oncology Source Type: research

Menopausal Hormone Therapy and Breast Cancer
Cancer J. 2022 May-Jun 01;28(3):169-175. doi: 10.1097/PPO.0000000000000601.ABSTRACTAssociations of estrogen-alone and estrogen plus progestin with breast cancer incidence and related mortality are reviewed from observational studies (The Collaborative Group on Hormonal Factors in Breast Cancer and The Million Women Study, 2019) and the Women's Health Initiative's (2020) two randomized trials evaluating conjugated equine estrogen alone, for women with prior hysterectomy or with medroxyprogesterone acetate. Findings are generally concordant for estrogen plus progestin use with both observational and randomized studies report...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Rowan T Chlebowski JoAnn E Manson Source Type: research

Pages: 1  2  3  4  5